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Abstract: Lung volume reduction surgery (LVRS) for symptomatic patients with advanced emphysema
was proven to be successful in a large randomized multi-center trial (NETT) and in several smaller
randomized single center trials. This evidence primarily concerns patients with heterogeneous, upper-
lobe predominant emphysema and low exercise tolerance within certain selection criteria regarding lung
function values. As the most important effect of LVRS is generated by reducing the hyperinflation, even
patients with homogeneous emphysema morphology profit from the procedure. Simultaneously, by remov-
ing distended and functionless areas in heterogeneous emphysema, also patients with seriously impaired
diffusion capacity, moderate pulmonary arterial hypertension, a history of previous LVRS and alpha-1-
antitrypsin-deficiency (AATD) can be considered as candidates for (re-)-LVRS. This article summarizes
indications for LVRS in these various subtypes of emphysema patients.
DOI: https://doi.org/10.21037/jtd.2018.08.93
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-164966
Journal Article
Published Version
Originally published at:
Caviezel, Claudio; Schneiter, Didier; Opitz, Isabelle; Weder, Walter (2018). Lung volume reduction
surgery beyond the NETT selection criteria. Journal of Thoracic Disease, 10(Suppl 23):S2748-S2753.
DOI: https://doi.org/10.21037/jtd.2018.08.93
© Journal of Thoracic Disease. All rights reserved. jtd.amegroups.com J Thorac Dis 2018;10(Suppl 23):S2775-S2779
Introduction
The aim of lung volume reduction surgery (LVRS) for 
patients suffering from severe emphysema is to improve 
lung function and quality of life by reducing dyspnea. 
For carefully selected patients with severe emphysema 
and hyperinflation, LVRS can be performed as a safe and 
effective treatment in a specialized high-volume center.
Emphysema and chronic bronchitis are two conditions 
that define chronic obstructive pulmonary disease (COPD). 
Smoking is the leading cause of COPD worldwide (1). 
Treatment of COPD may slower progression but cannot 
reverse damage to the parenchyma. In addition to medical 
therapy, surgical lung volume reduction was shown 
to improve lung function and quality of life (2). The 
National Emphysema Treatment Trial (NETT) was the 
first randomized multi-center trial comparing LVRS with 
medical treatment in patients with severe emphysema. 
Compared to the medically treated group, the LVRS group 
(>500 patients), had a much more significant improvement 
of lung function, walking distance, quality of life and 
even survival (2). Besides lung-transplantation, LVRS 
remains one of the most valuable treatment-options for 
patients suffering from severe emphysema. Careful patient 
selection in a multidisciplinary approach is mandatory for 
best possible outcome. By resection of the most destroyed 
areas, hyperinflation of the lung can be reduced and in 
combination with reshaping of the diaphragm lung function 
will improve (3).
Over the past decade, in specialized centers video-
assisted-thoracoscopic approach has become gold standard 
for LVRS (4). First description of bilateral thoracoscopic 
LVRS was reported in 1996 (5). At our institution, we 
started our LVRS-program in 1993 performing a bilateral 
thoracoscopic approach, which was the first world wide. 
In the majority, we performed bilateral one-staged LVRS. 
In 1996 McKenna and colleagues reported comparable 
morbidity, mortality and mean length of stay for unilateral 
and bilateral procedures but substantially better benefit for 
bilateral resection (6).
Homogenous and heterogeneous emphysema causes 
hyperinflation of the lung and therefore, patients 
with both entities can benefit from LVRS. However, 
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best evidence exists for heterogeneous upper-lobe 
predominant emphysema (2). By removing the most 
affected parenchyma and therefore reducing hyperinflation, 
the flattened diaphragm regains its dome-like shape. This 
increases diaphragmatic muscle strength and increases 
lung function. This is why measuring hyperinflation by 
body-plethysmography is one of the key factors for patient 
selection. However, as reported in the NETT, distribution-
heterogeneity was demonstrated as the most important 
selection criterion for LVRS. Patients with homogenous 
emphysema disease show a higher risk for morbidity and 
mortality after LVRS (2). Furthermore, unacceptable high 
mortality rates have been demonstrated in subgroups of 
patients in the NETT trial: patients with very low forced 
expiratory volume in 1 second (FEV1 <20% predicted) and 
homogenous emphysema and/or a low diffusion capacity 
[diffusing capacity for carbon monoxide (DLCO) <20% 
predicted] (2).
Postoperative complications and management
To minimize postoperative complications after LVRS, the 
thoracic surgery unit should perform a certain amount 
of cases a year. Although there is no data on the exact 
amount of operations per year and the overall experience, 
in analogy to technical demanding procedures as video-
assisted thoracoscopic surgery (VATS)-lobectomy, a minimal 
experience of 30 procedures and an annual number of 20 
should be required. Furthermore, careful patient selection 
after multidisciplinary discussion is mandatory. Several 
factors have been reported to increase morbidity and 
mortality: Advanced age, hypercapnia, cachexia, homogenous 
distribution of emphysema, pulmonary hypertension, low 
diffusion capacity, low forced expiratory volume, repeated 
hospitalizations due to recurrent infection and patients 
with steroid therapy (2,7-11). Importantly, smoking 
increases postoperative morbidity and mortality (12), 
therefore patients ideally stop smoking at least 6 to 
12 weeks prior to LVRS (13). In the NETT, a four months 
non-smoking status was required prior to surgery (2). In our 
institution, patients undergoing any kind of interventional 
treatment for emphysema, need to have quit smoking at 
least six months before.
To achieve the best postoperative outcome, multidisciplinary 
patient care, including thoracic surgeons, anesthesiologists, 
pulmonologists, physiotherapy and nursing staff is mandatory. 
Due to frequently associated comorbidities in COPD 
patients, preoperative optimization of medical therapy 
including pulmonary rehabilitation might reduce incidence of 
postoperative complications (14). 
The National Emphysema Trial documented 91% of 
patients without intraoperative complications but around 
60% faced at least one postoperative complication. In total of 
41.3% of patients showed pulmonary morbidity after surgery 
and about 20% had major cardio-vascular morbidity (2).
Most frequent complications after LVRS are of 
pulmonary origin, especially air leak. Failure for early 
extubation resulting in prolonged ventilation with need 
for tracheostomy and pneumonia are extremely rare. In 
addition, cardiac complications including arrhythmias, 
myocardial infarction and pulmonary embolus have been 
frequently reported. Gastro-intestinal complications may 
also be increased in LVRS patients (15). In the following 
chapter, we will focus on the different types of postoperative 
complications, their prevention and management. 
Pulmonary morbidity
Air leak
Air leak is the most common complication after LVRS. 
Prolonged air leak is defined as an air leak lasting more than 
5–7 days after surgery. Ciccone and colleagues reported 
that up to 45.2% of patients present prolonged air leak after 
LVRS (16). In the NETT data, there was no significant 
difference between median sternotomy and VATS approach 
regarding the occurrence of air leaks (2). The use of inhaled 
steroids, impaired lung function (lower diffusion capacity), 
homogenous emphysema and most important the degree of 
pleural adhesions are primary factors influencing prevalence 
and duration of air leak (17). As reported in the NETT, 
reoperation due to persistent air leak was required in up to 
5% of patients (2). Subcutaneous emphysema was increased 
in patients after a VATS approach compared to patients after 
a median sternotomy, occurring in around 5 to 10% (18).
Prevention of air-leaks would be the most efficient way to 
reduce several complications. In order to avoid air leaks during 
surgery, adapted techniques play an important role. The use 
of buttressed staple lines was shown to reduce the incidence 
of air leaks and the time to remove the chest tube (19). 
In addition, autologous fibrin sealant can decrease the 
incidence of prolonged air leak and duration of chest tube 
after LVRS (20). However, a Cochrane systematic review 
of 1,642 patients concluded in a non-recommendation for 
routine use of surgical sealants (21). Important prevention 
strategies include minimizing dissection within the 
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fissures, avoiding overlapping parenchymal staples lines 
or excessive resections. If pleural adhesions are present, 
careful dissection has to be performed, as emphysema 
lung parenchyma is very fragile. If the video-assisted 
thoracoscopic approach does not ensure proper adhesiolysis, 
we recommend conversion to thoracotomy in order to 
lessen parenchymal trauma. At the end of resection, the 
lung should be carefully re-inflated under vision control 
to assure the remaining lung is expanding completely and 
reaches the parietal pleura. Due to the contact of both 
visceral and parietal pleura, superficial air leaks will heal 
faster and drainage time is reduced. When re-inflating 
the lungs and during the period of extubation, inspiratory 
pressures should be as low as possible. Switching from 
double-lumen-tube to laryngeal mask (LAMA) was shown 
to prevent coughing with height pressure on stapler-lines 
during extubation. Early extubation in the operation theatre 
is a key factor to reduce occurrence and extent of air leak.
Despite all these precaution-maneuvers, around 30% 
of all our patients after LVRS present with prolonged air 
leak and around 10% of them will need revision surgery 
for fistula closure. The relatively high incidence in our 
cohort is probably due to the more aggressive approach 
when prolonged air leak is associated with progressive 
subcutaneous emphysema. 
Whether or not the chest drain should be held under 
permanent suction and what level of suction was addressed 
in several studies. There are no data about length and 
strength of suction in LVRS-patients. If tolerated by the 
patient, the chest drain might be connected to a Heimlich 
valve without suction in order to increase patient mobility 
even if a small amount of air leak is present. Thus, length 
of hospital stay can be reduced by discharging patients with 
chest tube in place. The median postoperative length of stay 
in our patient cohort is 11 days, the literature shows values 
between 10 to 14 days (22-24). 
Pneumonia
Pneumonia is considered the second most common 
pulmonary complication after LVRS. In the NETT, about 
18% of patients developed pneumonia postoperatively (2). 
Failure to early extubation and necessity for tracheostomy 
have been reported in 3.9% and 8.2%, respectively (2). 
In order to minimize infectious complications, at our 
institution prophylactic antibiotic therapy is started one 
hour before surgery and continued until the last drain has 
been removed. Due to marginal pulmonary capacity in 
these fragile group of patients, our approach to antibiotic 
therapy is rather liberal. If pneumonia occurs, antibiotic 
therapy needs to be tailored to microbiological findings if 
available. Up to today, there is no perioperative evidence-
based antibiotic management protocol available for 
LVRS patients. Postoperative early extubation and early 
mobilization are important in order to prevent infectious 
complications. Inhalation therapy and the use of incentive 
spirometry should be instructed before the procedure and 
continued immediately after surgery. Therefore, careful 
pain management with epidural anesthesia to enable 
early mobilization and respiratory therapy is fundamental 
to prevent side effects of opioid treatment (sleepiness 
with risk of aspiration) and pneumonia (25). In order to 
ensure patient mobility and reduce the risk of catheter 
complications, epidural catheter should be removed within 
2 to 3 days postoperatively. The NETT reported that 0,8% 
of patients developed epidural catheter complications (2).
Cardiac morbidity
Cardiac complications including arrhythmia, myocardial 
infarction and pulmonary emboli are reported after LVRS 
in analogy to other thoracic interventions. Arrhythmia 
is considered as the most frequent cardiac complication 
after LVRS. Within the NETT around 22% of patients 
developed postoperative arrhythmia requiring further 
medical therapy (2). Myocardial infarction and pulmonary 
embolus were reported within 1 and 0.8% respectively (2).
Arrhythmia
Atrial arrhythmia is the most common but rare arrhythmia 
after LVRS. Postoperative fluid overload, hypoxia 
and atelectasis can cause atrial arrhythmias. Careful 
postoperative fluid management and preventing fluid 
overload by use of diuretics can avert the occurrence of 
postoperative arrhythmias. Generally, in normo-frequent 
and asymptomatic patients, temporary adjustment of 
anticoagulation treatment is indicated. If patient shows 
clinical signs of depletion either pharmacological agents 
such as calcium channel blockers as well as amiodarone are 
used, or cardioversion is indicated. 
Thrombo-embolic disease
To prevent thrombo-embolic disease, prophylactic 
anticoagulation with unfractionated heparin is started 
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postoperatively in our institution. As reported by Geerts 
and colleagues, obesity, age over 40 years, medical history 
of previous thromboembolism, varices and estrogen use are 
important risk factors for venous thromboembolism (26). 
After bilateral LVRS, once chest drains are removed, we 
recommend therapeutic anticoagulation for 3 months 
following surgery. Oral anticoagulation can either be 
established with a vitamin-K antagonists or new oral 
factor-Xa-inhibitors such as rivaroxaban (Xarelto®). 
For vitamin-K antagonists, close monitoring and dose 
adjustments are necessary in order to obtain therapeutic 
anticoagulation, therefore we generally prefer to establish 
oral anticoagulation with factor-Xa-inhibitors. There is no 
recommendation for the use of oral anticoagulation after 
bilateral LVRS patients up to this date. 
Gastro-intestinal morbidity
As reported by Naunheim and colleagues’ gastro-intestinal 
complications after LVRS occur in about 6% of the patients (27). 
Diabetes, the use of corticosteroids as well as a higher 
number of pain medication have been documented to 
increase gastro-intestinal complications after LVRS (15). 
The occurrence of postoperative Ileus or Ogilvie’s syndrome 
might be related due to epidural catheter for pain relief 
postoperatively. Narcotic analgesics may increase the risk 
of gastro-intestinal depression. Due to these known adverse 
events, analgetic therapy should be selected carefully, 
particularly for patients who are of higher risk for gastro-
intestinal complications. 
Conclusions
Careful patient selection and anticipatory multidisciplinary 
patient care in a high-volume center are major keys to 
ensure the best postoperative outcome after LVRS. As 
reported in the NETT lung volume reduction can improve 
quality of life with low postoperative mortality and 
acceptable morbidity. In our institution, 30-day mortality 
rates were reported below 3% after thoracoscopic LVRS (28) 
in the past and is now below 0.5%. 
Preoperative preparation, vigilant surgical technique and 
anticipation of potential postoperative complications are 
mandatory for successful LVRS. 
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